Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Aldosterone-induced vasculopathy.

Allan D Struthers¹

¹Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, Dundee DD1 9SY, Scotland, UK.

Molecular and Cellular Endocrinology

|May 12, 2004

Summary

Aldosterone antagonists improve survival in chronic heart failure by preventing vascular damage. They counteract aldosterone's harmful effects, reducing tissue injury and fibrosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Association of bradykinin receptor 2 (BDKRB2) variants with physical performance and muscle mass: Findings from the LACE sarcopenia trial.

PloS one·2024

Same author

Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation.

Health technology assessment (Winchester, England)·2024

Same author

Activin type I receptor polymorphisms and body composition in older individuals with sarcopenia-Analyses from the LACE randomised controlled trial.

PloS one·2023

Same author

ACE I/D genotype associates with strength in sarcopenic men but not with response to ACE inhibitor therapy in older adults with sarcopenia: Results from the LACE trial.

PloS one·2023

Same author

Impact of beta-blockers on mortality and cardiovascular disease outcomes in patients with obstructive sleep apnoea: a population-based cohort study in target trial emulation framework.

The Lancet regional health. Europe·2023

Same author

Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial.

Lancet (London, England)·2022

Area of Science:

Cardiovascular Medicine
Endocrinology
Pathophysiology

Background:

Aldosterone antagonists are proven to reduce mortality in chronic heart failure (CHF).
The precise mechanisms underlying these benefits remain incompletely understood.
A leading hypothesis implicates aldosterone's detrimental effects on vascular health.

Purpose of the Study:

To elucidate the mechanism by which aldosterone antagonists exert their mortality-reducing effects in CHF.
To investigate the role of aldosterone-induced vasculopathy in the pathophysiology of CHF.

Main Methods:

Review of existing literature and prevailing hypotheses on aldosterone's role in CHF.
Analysis of the proposed pathway involving superoxide radicals, nitric oxide reduction, and subsequent tissue damage.

Main Results:

Aldosterone may induce vasculopathy by promoting superoxide radical generation, which degrades nitric oxide (NO).
This reduction in NO leads to impaired vascular function, tissue ischemia, and infarction.
The body's repair response to this injury involves fibrosis, contributing to disease progression.

Conclusions:

Aldosterone-induced vasculopathy, characterized by NO depletion and fibrosis, is a key mechanism driving tissue injury in CHF.
This vasculopathy may be the primary driver of aldosterone's adverse effects, leading to cardiac death.
Targeting aldosterone-induced vasculopathy represents a promising therapeutic strategy in managing chronic heart failure.

Related Experiment Videos